 |
|
|
| |
Anti-viral Proof of Concept Study of Miravirsen, an OligonucleotideTargeting miR-122, in Treatment Naïve Patients with Genotype 1 Chronic HCV Infection
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
AASLD: MicroRNA Drug Safe in Ongoing HCV Study - (11/21/11)
H. L. A. Janssen1; H. W. Reesink2; S. Zeuzem3; E. Lawitz4; M. Rodriguez-Torres5; A. Chen6; C. Davis6; B. King6; A. A. Levin6; M. R. Hodges6
1Erasmus MC University Hospital, Rotterdam, The Netherlands
2Academic Medical Center, Amsterdam, The Netherlands
3J.W. Goethe University Hospital, Frankfurt, Germany
4Alamo Medical Research, San Antonio, TX, United States
5Fundacionde Investigacionde Diego, San Juan, Puerto Rico
6Santaris PharmaA/S, San Diego, CA, United States
|
| |
|
|
|
|
|
